Abstract
As fetal gene therapies move from experimental animal models to human in utero phase I clinical trials, there is a need to consider the ethical, legal, and social implications. While fetal gene therapies are attracting more regulatory oversight than previous fetal interventions such as fetal surgery, old sociological questions should be applied to this new context. As health care pathways around fetal therapy are shaped by the ways in which a pregnant person and the fetus are constituted, and as risks and benefits are evaluated, we cannot afford to lose sight of long-term consequences, especially those pertaining to social inclusion.
| Original language | English |
|---|---|
| Pages (from-to) | 933-940 |
| Number of pages | 8 |
| Journal | Clinical Obstetrics and Gynecology |
| Volume | 64 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Dec 2021 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- ELSI
- fetal treatment
- gene therapy
- prenatal therapy
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver